Lynx1 Capital Management LP Pardes Biosciences, Inc. Transaction History

Lynx1 Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.4 - $1.95 $809,722 - $1.13 Million	578,373 Added 17.4%	3,902,434 $7.06 Million
Q1 2023 May 15, 2023	BUY	$1.21 - $2.22 $388,360 - $712,528	320,959 Added 10.69%	3,324,061 $4.39 Million
Q4 2022 Feb 14, 2023	BUY	$0.85 - $1.69 $618,264 - $1.23 Million	727,370 Added 31.96%	3,003,102 $5.08 Million
Q3 2022 Nov 14, 2022	BUY	$2.14 - $3.7 $203,668 - $352,136	95,172 Added 4.36%	2,275,732 $4.21 Million
Q2 2022 Aug 15, 2022	BUY	$2.84 - $8.57 $1.53 Million - $4.61 Million	537,726 Added 32.73%	2,180,560 $6.69 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $15.64 $7 Million - $19.4 Million	1,241,241 Added 309.08%	1,642,834 $11.9 Million
Q4 2021 Feb 14, 2022	BUY	$9.8 - $17.02 $3.94 Million - $6.84 Million	401,593 New	401,593 $6.57 Million

5.23M

Ticker PRDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,320,900
Description
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.